Voluntarily participate in the study, be able to understand, and sign the informed consent form.
Aged 18 to 45 years (inclusive) at the time of signing the informed consent form.
Assessed as high-risk for preeclampsia at gestational weeks 11-13, defined as either:
A risk value of ≥1/100 based on the simplified Fetal Medicine Foundation (FMF) model, OR A high-risk result from serum biomarker screening (sFlt-1, PLGF, sFlt-1/PLGF ratio). (See Appendix for details)
Gestational weeks 11-13 at enrollment.
Singleton intrauterine pregnancy (confirmed by transvaginal or transabdominal ultrasound).
You may not be if
History of psychiatric disorder not adequately controlled by medication.
Unexplained vaginal bleeding at screening.
Known uterine malformation.
Evidence of positive serology for HIV, HBV (HBsAg positive), HCV (anti-HCV antibody positive), or syphilis.
Known proliferative retinopathy.
Presence of severe organic disease or any other condition that, in the judgment of the investigator, makes the subject unsuitable for study participation.
Planned or current use of medications with potential drug-drug interactions with human granulocyte colony-stimulating factor (G-CSF) analogs, such as lithium.
Known allergy to rhG-CSF products or their components, or allergy to recombinant human proteins/peptides derived from E. coli.
